Fig. 6

Rocaglamide reduces R1881-induced increase in AR protein levels and transactivity. A Representative western blot to investigate the influence of Rocaglamide on the R1881-induced increase of AR protein in LNCaP, C4-2, and 22RV1 cells. In addition, p-eIF4E and eiF4E were investigated to assess the changes in eiF4F activity. Uncropped Western blots are displayed in Fig. 8B. B Densitometry of AR protein levels relative to TPS in LNCaP, C4-2, and 22RV1 cells. Relative expression levels after treatment were shown as mean ± SD of six independent experiments. All differences highlighted by asterisks were statistically significant (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001). C Densitometry of p-eiF4E protein levels relative to eiF4E in LNCaP, C4-2, and 22RV1 cells. Relative expression levels after treatment were shown as mean ± SD of five independent experiments. All differences highlighted by asterisks were statistically significant (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001). D Relative changes of AR transactivity to determine the influence of Enzalutamide (Enza), Cycloheximide (C6), and Rocaglamide (Roca) on the influence of R1881-induced increase of AR transactivity. Changes were assessed by changes in KLK3 normalised to HPRT1 mRNA determined by qPCR. Relative expression levels after treatment were shown as mean ± SEM of six independent experiments. All differences highlighted by asterisks were statistically significant (**p ≤ 0.01; ***p ≤ 0.001)